Cover Image
市場調查報告書

皮膚疾病治療藥的全球市場分析、預測:乾癬、皮膚感染疾病、痤瘡、皮膚炎、其他

Dermatological Drugs Market Forecast 2018-2028: Psoriasis, Skin Infection, Acne, Dermatitis, Others

出版商 Visiongain Ltd 商品編碼 233143
出版日期 內容資訊 英文 333 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
皮膚疾病治療藥的全球市場分析、預測:乾癬、皮膚感染疾病、痤瘡、皮膚炎、其他 Dermatological Drugs Market Forecast 2018-2028: Psoriasis, Skin Infection, Acne, Dermatitis, Others
出版日期: 2018年08月14日 內容資訊: 英文 333 Pages
簡介

2017年的全球皮膚疾病治療藥的市場記錄260億7000萬美元的收益規模,預計調查期間前半部分以5.8%的年複合成長率發展。

本報告提供全球皮膚疾病治療藥的市場調查,皮膚疾病及治療藥種類與概要,各藥物種類的市場規模、市場佔有率的變化與預測,主要產品概要與銷售情況與預測,各地區、主要國家的詳細分析,市場環境及市場的各種影響因素分析,開發平台趨勢,主要企業簡介等資訊彙整。

第1章 報告概要

第2章 皮膚疾病治療藥:簡介

  • 醫藥品產業:概要
  • 皮膚醫學概要
  • 一般的皮膚疾病
    • 痤瘡:最常見的皮膚疾病
    • 皮膚炎:皮膚的發炎
    • 乾癬:複雜的多因素性疾病
    • 酒糟:血管不穩定性
    • 脫髮症:異常的掉頭髮
  • 皮膚感染:嚴重的健康上的威脅
    • 細菌性皮膚感染
    • 菌性皮膚感染
    • 病毒性皮膚感染
  • 一般的皮膚疾病治療藥
    • 奶油、半固態乳劑
    • 軟膏
    • 化妝水
    • 液劑
    • 密封療法
    • 清洗劑
    • 粉末、親水性聚合物
    • 抗感染疾病劑
    • 抗發炎劑
  • 臨床試驗的階段
  • 在皮膚疾病治療藥:本報告書的市場定義

第3章 全球皮膚疾病治療藥市場分析、預測:各類藥物

  • 市場概要
  • 皮膚疾病治療藥的類別區分
  • 市場成果
  • 市場預測
  • 市場佔有率的變化、預測

第4章 市場分析、預測:乾癬治療藥

  • 乾癬治療藥:主流的生技藥品
    • 主要產品
  • 市場趨勢、發展趨勢
  • 市場預測
    • 市場佔有率的變化、預測
    • Humira (Adalimumab:Abbott)
    • Stelara (Ustekinumab:Johnson & Johnson)
    • Enbrel (Etanercept:Amgen、Pfizer、武田藥品工業)
    • Remicade (Infliximab:Johnson & Johnson)
    • Taltz (Ixekizumab:Eli Lily)
    • Otezla (Apremilast:Celgene)
    • Cosentyx (Secukinumab:Novartis)
    • 其他
  • 摘要

第5章 市場分析、預測:皮膚感染疾病治療藥

  • 皮膚感染治療藥:豐富的成長機會
    • 主要產品
  • 市場預測
    • 主要產品的市場佔有率的變化、預測
  • 主要藥物
    • Cubicin(daptomycin:Cubist 醫藥品、Merck & Co)
    • Zyvox (linezolid:Pfizer)
    • Canesten (Clotrimazole:Bayer)
    • Valtrex (valaciclovir:GSK)
    • Bactroban (mupirocin:GSK)
    • Lamisil (Terbinafine:Novartis)
    • 其他
  • 摘要

第6章 市場分析、預測:痤瘡治療藥

  • 痤瘡治療藥:多樣化的市場
    • 主要產品
  • 近幾年趨勢、發展趨勢
  • 市場預測
    • 主要產品的市場佔有率的變化、預測
  • 主要藥物
    • Epiduo (adapalene/過氧化苯甲醯:Galderma、Nestle Skin Health)
    • Solodyn (米諾四環素:Valeant)
    • Claravis (isotretinoin :Teva)
    • Aczone (Dapsone:Allergan)
    • Differin (adapalene:Galderma/Nestle Skin Health)
    • Absorica/Epuris (CIP-isotretinoin :Cipher/ Sun Pharma)
    • Ziana (clindamycin/tretinoin:Valeant)
    • Doryx (doxycycline:Actavis/ Mayne Pharma)
    • 其他
  • 摘要

第7章 市場分析、預測:皮膚炎治療藥

  • 皮膚炎治療藥:學名藥的高普及率
    • 主要產品
  • 市場預測
    • 主要產品的市場佔有率的變化、預測
  • 主要藥物
    • Bepanthen (dexpanthenol)/ Bepanthol
    • Elocon (mometasone:Merck & Co)
    • Protopic (Tacrolimus:LEO Pharma)
    • Dermovate (GSK)
    • 其他
  • 市場展望

第8章 主要國家市場預測

第9章 北美市場分析、預測

第10章 歐洲市場分析、預測

第11章 亞太地區市場分析、預測

第12章 南美市場分析、預測

第13章 中東、非洲市場分析、預測

第14章 主要企業的簡介

第15章 研發產品線的預測

第16章 定性分析

  • 市場的影響因素
  • SWOT分析
  • 波特的五力分析

第17章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0325

The revenue of the dermatological drugs market in 2017 is estimated at $26.07bn and is expected to grow at a CAGR of 5.8% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2017, this segment accounted for 36% of the global dermatological drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 333-page report you will receive 124 tables and 147 figures- all unavailable elsewhere.

The 333-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Dermatological drugs market forecasts from 2018-2028
  • This report also breaks down the revenue forecast for the main submarkets:
    • Psoriasis
    • Skin Infections
    • Acne
    • Dermatitis
  • Analysis of the Psoriasis drugs market. Revenue forecasts to 2028 are provided for the following drugs:
    • Humira
    • Stelara
    • Enbrel
    • Remicade
    • Taltz
    • Otezla
    • Cosentyx
  • Analysis of the Skin Infections drugs market. Revenue forecasts to 2028 are provided for the following drugs:
    • Cubicin
    • Zyvox
    • Valtrex
    • Canesten
    • Lamisil
    • Bactroban
  • Analysis of the Acne drugs market. Revenue forecasts to 2028 are provided for the following drugs:
    • Solodyn
    • Epiduo
    • Claravis
    • Aczone
    • Differin
    • Abscorical/Epirus
    • Ziana
    • Doryx
  • Analysis of the Dermatitis drugs market. Revenue forecasts to 2028 are provided for the following drugs:
    • Bepanthen/Bepanthol
    • Protopic
    • Dermovate
    • Elocon
  • This report provides individual revenue forecasts to 2028 for these regional and national markets:
    • North America: US & Canada
    • Europe: Germany, France, UK, Italy, Spain, Rest of Europe
    • Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
    • Latin America: Brazil, Mexico, Rest of Latin America
    • Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA

image1

Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.

  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.

Our study discusses the selected leading companies that are the major players in the dermatological drugs market: AbbVie Amgen Bayer AG Galderma (Nestle Skin Health S.A.) GlaxoSmithKline (GSK) Johnson & Johnson LEO Pharma Merck & Co, Inc. Novartis Pfizer

Our new report discusses issues and events affecting the dermatological drugs market:

  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future paradigm-shifting pipeline products
  • Patent expirations
  • Launches of new drug categories
  • Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance

Visiongain's study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Dermatological Drugs Market Overview
  • 1.2 Overview of Findings
  • 1.3 Structure of the Report
  • 1.4 Global Dermatological Drugs Market Segmentation
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Key Questions Answered by This Analytical Report
  • 1.8 Who is This Report For?
  • 1.9 Methodology
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to Dermatological Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
  • 2.2 An Introduction to Dermatology
    • 2.2.1 The Structure of Skin, Hair, and Nails
    • 2.2.2 Hair and Nails
    • 2.2.3 Sweat and Sebaceous Glands
    • 2.2.4 Functions of the Skin
  • 2.3 Common Skin Diseases
    • 2.3.1 Acne: The Most Common Skin Disease
      • 2.3.1.1 Acne: Epidemiology
      • 2.3.1.2 Acne: Causes and Pathogenesis
      • 2.3.1.3 Acne: Treatment
    • 2.3.2 Dermatitis: Inflammation of the Skin
      • 2.3.2.1 Atopic Dermatitis
      • 2.3.2.2 Contact Dermatitis
      • 2.3.2.3 Seborrhoeic Dermatitis
      • 2.3.2.4 Nummular Dermatitis
      • 2.3.2.5 Perioral Dermatitis
    • 2.3.3 Psoriasis: A Complex Multi-Factorial Disease
    • 2.3.4 Rosacea: Vascular Instability
    • 2.3.5 Alopecia: Excessive Shedding of Hair
  • 2.4 Skin Infections: A Serious Healthcare Threat
    • 2.4.1 Bacterial Skin Infections
    • 2.4.2 Fungal Skin Infections
    • 2.4.3 Viral Skin Infections
  • 2.5 Common Skin Treatments
    • 2.5.1 Creams and Semisolid Emulsions
    • 2.5.2 Ointments
    • 2.5.3 Lotions
    • 2.5.4 Solutions
    • 2.5.5 Occlusive Therapy
    • 2.5.6 Cleansing Agents
    • 2.5.7 Powders and Hydrophilic Polymer
    • 2.5.8 Anti-Infective Agents
    • 2.5.9 Anti-Inflammatory Agents
  • 2.6 Phases of Clinical Trials
  • 2.7 Dermatological Drugs: Market Definition in this Report

3. Global Dermatological Drugs Market, by Drugs Class 2018-2028

  • 3.1 The Global Dermatological Drugs Market: Market Overview
  • 3.2 Categorisation of the Global Dermatological Drugs Market
  • 3.3 The Global Dermatological Drugs Market in 2017
  • 3.4 The Global Dermatological Drugs Market: Market Forecast 2018-2028
  • 3.5 Changing Market Shares by Segment 2018-2028

4. The Psoriasis Drugs Market: Market Analysis and Forecast 2018-2028

  • 4.1 Psoriasis Treatments: The Dominance of Biologics
    • 4.1.1 Leading Products in the Psoriasis Drugs Market, 2017
  • 4.2 Psoriasis: Market Trends and Developments, 2017
    • 4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
    • 4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
    • 4.2.3 Biosimilars and Interchangeables
      • 4.2.3.1 Extrapolation of indications
      • 4.2.3.2 Biosimilar interchangeability in the EU
      • 4.2.3.3 Biosimilar guidance in the US
      • 4.2.3.4 The Disadvantages of Biologics in Psoriasis Treatment
  • 4.3 Psoriasis Drugs: Market Forecast 2018-2028
    • 4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2018-2028
      • 4.4 Leading Drugs Used in the Treatment of Psoriasis
    • 4.4.1 Humira (adalimumab) - AbbVie
      • 4.4.1.1 Humira: Historical Sales Analysis, 2010-2017
      • 4.4.1.2 Humira: Sales Forecast 2018-2028
      • 4.4.1.3 Future Prospects for Biosimilar Versions of Humira
    • 4.4.2 Stelara (ustekinumab) - Johnson & Johnson
      • 4.4.2.1 Stelara New Market Leader, Ahead of Humira
      • 4.4.2.2 Stelara: Historical Sales Analysis, 2010-2017
      • 4.4.2.3 Stelara: Sales Forecast 2018-2028
      • 4.4.2.4 Intensifying Competition for Stelara
    • 4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
      • 4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
      • 4.4.3.2 Enbrel: Historical Sales Analysis, 2009-2017
      • 4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2018-2028
      • 4.4.3.4 Patent Litigation with Sandoz Over Enbrel
      • 4.4.3.5 Enbrel: Sales Forecast 2018-2028
      • 4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
      • 4.4.3.7 Competition from Other Drugs
      • 4.4.3.8 Biosimilar Competition for Enbrel
    • 4.4.4 Remicade (infliximab) - Johnson & Johnson
      • 4.4.4.1 Remicade: Historical Sales Analysis, 2009-2017
      • 4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2018-2028
      • 4.4.4.3 Remicade: Sales Forecast 2018-2028
    • 4.4.5 Taltz (ixekizumab) - Eli Lilly
      • 4.4.5.1 Taltz: Sales Forecast 2018-2028
    • 4.4.6 Otezla (apremilast) - Celgene
      • 4.4.6.1 Otezla: Sales Forecast 2018-2028
    • 4.4.7 Cosentyx (secukinumab) - Novartis
      • 4.4.7.1 Cosentyx: Sales Forecast 2018-2028
    • 4.4.8 Other Psoriasis Drugs
      • 4.4.8.1 Cimzia (certolizumab) - UCB
      • 4.4.8.2 Sorilux (calcipotriene foam) - GSK
      • 4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
      • 4.4.8.4 Other Psoriasis Drugs: Sales Forecast 2018-2028
  • 4.5 Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis and Forecast 2018-2028

  • 5.1 Skin Infection Drugs: Abundant Growth Opportunities
    • 5.1.1 Leading Products in the Skin Infection Drugs Market, 2017
  • 5.2 Skin Infection Drugs: Market Forecast 2018-2028
    • 5.2.1 Skin Infection: Changing Market Shares by Leading Drugs 2018-2028
  • 5.3 Leading Drugs Used in the Treatment of Skin Infections
    • 5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
    • 5.3.2 Acquisition by Merck & Co
    • 5.3.3 Generic Competition for Cubicin
    • 5.3.4 Cubicin: Sales Forecast 2018-2028
    • 5.3.5 Lifecycle Management Strategies for Cubicin
  • 5.4 Zyvox (linezolid) - Pfizer
    • 5.4.1 Zyvox: Historical Sales Analysis, 2010-2017
    • 5.4.2 Zyvox: Sales Forecast 2018-2028
    • 5.4.3 The Threats to Zyvox Sales from Competing New Drugs
  • 5.5 Canesten (clotrimazole) - Bayer
    • 5.5.1 Canesten: Historical Sales Analysis, 2011-2017
    • 5.5.2 Canesten: Sales Forecast 2018-2028
  • 5.6 Valtrex (valaciclovir) - GSK
    • 5.6.1 Valtrex: Historical Sales Analysis, 2010-2017
    • 5.6.2 Valtrex: Sales Forecast 2018-2028
  • 5.7 Bactroban (mupirocin) - GSK
    • 5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
    • 5.7.2 Bactroban: Sales Forecast 2018-2028
  • 5.8 Lamisil (terbinafine) - Novartis
    • 5.8.1 Lamisil Patent Expiry
    • 5.8.2 Lamisil Sales Affected by Novartis Manufacturing Problems
    • 5.8.3 Lamisil: Sales Forecast 2018-2028
  • 5.9 Other Skin Infection Drugs
    • 5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
    • 5.9.2 Jublia (efinaconazole) - Valeant
    • 5.9.3 Kerydin (tavaborole) - Anacor
    • 5.9.4 Sivextro (tedizolid) - Cubist Pharmaceuticals
    • 5.9.5 Zovirax (acyclovir) - Valeant/GSK
    • 5.9.5.1 Valeant Acquires Zovirax in US and Canada
    • 5.9.5.2 Mylan"s Generic Zovirax and Actavis" Authorised Generic
    • 5.9.6 Other Skin Infection Drugs: Sales Forecast 2018-2028
  • 5.10 Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis and Forecast 2018-2028

  • 6.1 Acne Drugs: A Diversified Market
    • 6.1.1 Leading Products in the Acne Drugs Market, 2017
  • 6.2 Acne Drugs Market: Recent Trends and Developments
    • 6.2.1 The Rise of Combination Therapies in Acne Treatment
    • 6.2.2 Oral Contraceptives in Treating Acne
    • 6.2.3 The Threat of Generic Competition in the Acne Drugs Market
  • 6.3 Acne Drugs: Market Forecast 2018-2028
    • 6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2018-2028
  • 6.4 Leading Drugs in the Acne Drugs Market
    • 6.4.1 Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health
      • 6.4.1.1 Epiduo: Sales Forecast 2018-2028
      • 6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
      • 6.4.1.3 Paediatric Approval for Epiduo
    • 6.4.2 Solodyn (minocycline) - Valeant
      • 6.4.2.1 Solodyn: Sales Forecast 2018-2028
      • 6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
      • 6.4.2.3 Impax and Medicis Collaborating on Advanced Solodyn
      • 6.4.2.4 Medicis and Lupin Settle
    • 6.4.3 Claravis (isotretinoin) - Teva
      • 6.4.3.1 Claravis: Sales Forecast 2018-2028
    • 6.4.4 Aczone (dapsone) - Allergan
      • 6.4.4.1 Aczone: Sales Forecast 2018-2028
    • 6.4.5 Differin (adapalene) - Galderma/ Nestlé Skin Health
      • 6.4.5.1 Recent Generic Competition to Differin
      • 6.4.5.2 Differin: Sales Forecast 2018-2028
      • 6.4.5.3 Adapalene Gel to be Available OTC in the US
      • 6.4.5.4 Federal Circuit Court Invalidates Differin Patents
    • 6.4.6 Absorica/Epuris (CIP-isotretinoin) - Cipher/Sun Pharma
      • 6.4.6.1 Absorica/Epuris: Sales Forecast 2018-2028
    • 6.4.7 Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
      • 6.4.7.1 Valeant"s Patent Settlement with Actavis over Ziana
      • 6.4.7.2 Ziana: Sales Forecast 2018-2028
    • 6.4.8 Doryx (doxycycline) - Actavis/Mayne Pharma
      • 6.4.8.1 Lifecycle Management Strategies for Doryx
      • 6.4.8.2 Divestment Agreement with Mayne Pharma
      • 6.4.8.3 Generic Competition for Doryx
      • 6.4.8.4 Doryx: Sales Forecast 2018-2028
    • 6.4.9 Other Acne Drugs
      • 6.4.9.1 Acanya (clindamycin/benzoyl peroxide) - Dow
        • 6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya
        • 6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, and Watson
      • 6.4.9.2 Amnesteem (isotretinoin) - Mylan
        • 6.4.9.2.1 Amnesteem: Financial Analysis
      • 6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
      • 6.4.9.4 Duac (clindamycin/benzoyl peroxide) -
      • 6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
      • 6.4.9.6 Other Acne Drugs: Sales Forecast 2018-2028
  • 6.5 Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis and Forecast 2018-2028

  • 7.1 Dermatitis Drugs: High Generic Penetration
    • 7.1.1 Leading Products in the Dermatitis Drugs Market, 2017
  • 7.2 Dermatitis Drugs: Market Forecast 2018-2028
    • 7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2018-2028
  • 7.3 Leading Drugs in the Dermatitis Drugs Market
    • 7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
      • 7.3.1.1 Bepanthen: Sales Forecast 2018-2028
    • 7.3.2 Elocon (mometasone) - Merck & Co
      • 7.3.2.1 Elocon: Sales Forecast 2018-2028
    • 7.3.3 Protopic (tacrolimus) - LEO Pharma
      • 7.3.3.1 Protopic Benefits from Expanded Indication
      • 7.3.3.2 Generic Competition for Protopic
      • 7.3.3.3 Protopic: Sales Forecast 2018-2028
    • 7.3.4 Dermovate -GSK
      • 7.3.4.1 Dermovate: Sales Forecast 2018-2028
    • 7.3.5 Other Dermatitis Drugs: Sales Forecast 2018-2028
  • 7.4 Dermatitis Drugs: Market Outlook

8. Leading National Markets 2018-2028

  • 8.1 Geographical Breakdown of the World Dermatological Drugs Market
  • 8.2 World Dermatological Drugs Market: Regional Forecast 2018-2028
    • 8.2.1 How Will Regional Market Shares Change to 2028?

9. North America Dermatological Drugs Market 2018-2028

  • 9.1. U.S. Dermatological Drugs Market: Trends and Developments
    • 9.1.1. Obamacare Repeal
    • 9.1.2. Legislative Environment Stimulating Biosimilars
    • 9.1.3 Biosimilar Interchangeability guidance in the US
    • 9.1.4 US Dermatological Drugs Market: Market Forecast 2018-2028
  • 9.2. Canada Dermatological Drugs Market: Trends and Developments

10. Europe Dermatological Drugs Market 2018-2028

  • 10.1 Europe Markets: Changing Market Shares by Country, 2018-2028
  • 10.2 Germany
    • 10.2.1 Germany Dermatological Drugs Market: Market Forecast 2018-2028
  • 10.3. France Dermatological Drugs Market Forecast 2018-2028
  • 10.4. U.K.
    • 10.4.1 The Impact of Brexit On the Dermatological Drugs
    • 10.4.2 Pricing and Reimbursement
    • 10.4.3 New Regulatory Body and Clinical Trials
    • 10.4.4 Patent Protection
    • 10.4.5 Research and Funding
    • 10.4.6. U.K. Dermatological Drugs Market Forecast 2018-2028
  • 10.5 Italy
    • 10.5.1 Italy Dermatological Drugs Market Forecast 2018-2028
  • 10.6. Spain Dermatological Drugs Market Forecast 2018-2028
  • 10.7. Rest of Europe Dermatological Drugs Market Forecast 2018-2028
    • 10.7.1 Russia
      • 10.7.1.1 Pharma2020 Strategy - Healthcare and Industry Reform

11. Asia-Pacific Dermatological Drugs Market 2018-2028

  • 11.1 China
    • 11.1.1 Expansion of Healthcare Coverage and Reimbursement in China
    • 11.1.2 Improving Public Perception of Dermatology in China
    • 11.1.3 Price Controls and the Anhui Model
    • 11.1.4 Chinese Dermatological Drugs Market Forecast 2018-2028
  • 11.2. Japan Dermatological Drugs Market: Trends and Developments
    • 11.2.1 The Cost of Treatment in Japan
    • 11.2.2 Japanese Pharmaceutical Industry Regulatory Reform
    • 11.2.3 Japanese Dermatological Drugs Market Forecast
  • 11.3. India
    • 11.3.1 The Effects of the Drug Prices Control Order of 2013
    • 11.3.2 India"s Expansion of Healthcare Provision
    • 11.3.3 Revised Biosimilar Guidelines
    • 11.3.4 Indian Dermatological Drugs Market Forecast 2018-2028
  • 11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments

12. Latin America Dermatological Drugs Market 2018-2028

  • 12.1 Brazil
    • 12.1.1 The Growth in Brazil"s Healthcare Landscape
    • 12.1.2 Clearer Access to Medicines in Brazil
    • 12.1.3 Brazil Dermatological Drugs Market Forecast 2018-2028
  • 12.2. Mexico Dermatological Drugs Market: Trends and
  • 12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments

13. Middle East & Africa Dermatological Drugs Market 2018-2028

  • 13.1. Saudi Arabia Dermatological Drugs Market Forecast 2018-2028
  • 13.2. South Africa Dermatological Drugs Market Forecast 2018-2028
  • 13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2018-2028

14. Leading Companies in the Dermatological Drugs Market

  • 14.1. Galderma (Nestle Skin Health S.A.)
    • 14.1.1 Galderma: Dermatological Drugs Product Portfolio
    • 14.1.2 Financial Overview
    • 14.1.3 Recent Transactions Summary
  • 14.2. Johnson & Johnson
    • 14.2.1 Johnson & Johnson: Dermatological Drugs Product Portfolio
    • 14.2.2 Financial Overview
    • 14.2.2.1 Pipeline, 2018
    • 14.2.3 Recent Transactions Summary
  • 14.3. GlaxoSmithKline plc
    • 14.3.1 GlaxoSmithKline plc: Dermatological Drugs Portfolio
    • 14.3.2 GlaxoSmithKline plc: Financial Overview
    • 14.3.3 GlaxoSmithKline plc: Recent Transactions Summary
  • 14.4. Pfizer, Inc.
    • 14.4.1 Pfizer, Inc.: Dermatological Drugs Portfolio
    • 14.4.2 Pfizer, Inc.: Financial Overview
    • 14.4.3 Pfizer, Inc.: Recent Developments
    • 14.4.4 Pfizer: Dermatological Drugs Development Pipeline, 2018
  • 14.5.LEO Pharma A/S
    • 14.5.1 LEO Pharma A/S.: Dermatological Drugs Product Portfolio
    • 14.5.2 Financial Overview
    • 14.5.3 Recent Transactions Summary
  • 14.6. AbbVie Inc.
    • 14.6.1 AbbVie Inc.: Dermatological Drugs Product Portfolio
    • 14.6.2 Financial Overview
    • 14.6.3 Recent Transactions Summary
  • 14.7. Novartis AG
    • 14.7.1 Novartis: Dermatological Drugs Portfolio
    • 14.7.2 Novartis: Financial Overview
    • 14.7.3 Novartis: Recent Developments
  • 14.8. Amgen, Inc.
    • 14.8.1 Amgen, Inc.: Dermatological drugs Portfolio
    • 14.8.2 Financial Overview
    • 14.8.3 Recent Transactions Summary
  • 14.9 Merck & Co., Inc.
    • 14.9.1 Merck & Co., Inc.: Dermatological Drugs Portfolio
    • 14.9.2 Merck & Co., Inc.: Financial Overview
    • 14.9.3 Merck & Co., Inc.: Recent Transactions Summary
  • 14.10 Bayer AG
    • 14.10.1 Bayer AG: Dermatological Drugs Portfolio
    • 14.10.2 Bayer AG: Financial Overview
    • 14.10.3 Bayer AG: Recent Transactions Summary

15. Dermatological Drugs: Research and Development Pipeline, 2018-2028

  • 15.1 Innovative Products Currently in Development Will Drive Growth
    • 15.1.1 New Technology in R&D Pipeline Activities
      • 15.1.1.1 Reformulation
      • 15.1.1.2 Combination Treatments
      • 15.1.1.3 New Mechanisms and Drug Delivery Technologies
      • 15.1.1.4 Potential Market Entrants
  • 15.2 Psoriasis Drugs Development Pipeline, 2017
    • 15.2.1 Psoriasis Drugs in Phase 3 Development or
      • 15.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
    • 15.2.2 Psoriasis Drugs in Phase 2 Development
      • 15.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
      • 15.2.2.2 PH-10 (Rose Bengal) - Provectus
    • 15.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical
  • 15.3 Skin Infection Drugs Development Pipeline, 2018
    • 15.3.1 Drugs in Phase 3 Development for Skin Infections
      • 15.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
      • 15.3.1.2 NB-001 - NanoBio Corporation
      • 15.3.1.3 Luliconazole - Topica Pharmaceuticals
    • 15.3.2 Drugs in Phase 2 Development for Skin Infections
    • 15.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
  • 15.4 Acne Drugs Development Pipeline, 2017
    • 15.4.1 Drugs in Phase 3 Development for Acne
      • 15.4.1.2 Visonac (photodynamic therapy) - Photocure
      • 15.4.2 Drugs in Phase 2 Development for Acne
      • 15.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
      • 15.4.4 A Possible Vaccine for Acne
  • 15.5 Dermatitis Drugs Development Pipeline, 2017
    • 15.5.1 Drugs in Phase 3 Development for Dermatitis
      • 15.5.1.1 Toctino (alitretinoin) - GSK
      • 15.5.1.2 Dermadexin and Pruridexin (P3CGM) - Cipher
      • 15.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre
      • 15.5.1.4 REGN668/SAR231893 (dupilumab) -
    • 15.5.2 Drugs in Phase 2 Development for Dermatitis
    • 15.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
  • 15.6 Other Dermatological Drugs Development Pipeline, 2017
    • 15.6.1 Other Dermatological Drugs: Filed or Recently
      • 15.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
      • 15.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
      • 15.6.1.3 Mirvaso (brimonidine) - Galderma
      • 15.6.1.4 Picato (ingenol mebutate) - LEO Pharma
      • 15.6.1.5 Xolair (omalizumab) - Novartis/ Roche
    • 15.6.2 Other Dermatological Drugs: Phase 3 Pipeline
      • 15.6.2.1 CD5024 (ivermectin) - Galderma
      • 15.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E
    • 15.6.3 Other Dermatological Drugs: Phase 2 Pipeline

16. Qualitative Analysis of the Dermatological Drugs Market, 2018-2028

  • 16.1 Market Factors Influencing Dermatological Drugs
  • 16.2 SWOT Analysis of the Global Dermatological Drugs Market, 2018-2028
    • 16.2.1 Strengths
      • 16.2.1.1 The High Unmet Clinical Need in Dermatology
      • 16.2.1.2 A Healthy Pipeline of Development-Stage Products
      • 16.2.1.3 Strong Industry-Physician Relationships
    • 16.2.2 Weaknesses
      • 16.2.2.1 Limited Efficacy and Adverse Effects May Impact
      • 16.2.2.2 Patient Adherence - A Major Challenge to
      • 16.2.2.3 Impending Patent Expiries and the Challenges
    • 16.2.3 Opportunities
      • 16.2.3.1 The High-Growth Sectors in Dermatology
      • 16.2.3.2 Personalised Dermatology: Technological Advances in Genomics
      • 16.2.3.3 Advances in Topical Drug Delivery Methods Offers
      • 16.2.3.4 Consolidation within Dermatology - Opportunity for Synergistic Growth?
    • 16.2.4 Threats
      • 16.2.4.1 Uncertainty Surrounding Reimbursement and
      • 16.2.4.2 The Rising Cost of Research and Development
      • 16.2.4.3 Downward Pressures on Drug Prices
  • 16.3 Porter's Five Force Analysis of the Global Dermatological Drugs Market, 2018-2028
    • 16.3.1 Threat of New Entrants
    • 16.3.2 Threat of Substitutes
    • 16.3.3 Rivalry among Competitors
    • 16.3.4 Power of Buyers
    • 16.3.5 Power of Suppliers

17. Conclusions

  • 17.1 Overview of Current Market Conditions and Market Forecast, 2018-2028
  • 17.2 Leading Sectors in Dermatological Drugs in 2017
  • 17.3 Leading Regions in the Dermatological Drugs Market in 2017
  • 17.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2018-2028
  • 17.5 What Does the Future Hold for Dermatological Drugs?

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Clinical Trial Phases, 2017
  • Table 3.1 Global Dermatological Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
  • Table 3.2 Global Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 3.3 Global Dermatological Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 4.1 Global Psoriasis Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
  • Table 4.2 Global Psoriasis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 4.3 Global Psoriasis Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 4.4 Global Humira Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 4.5 Global Humira Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.6 Global Stelara Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 4.7 Global Stelara Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.8 Global Enbrel Market Forecast: Revenues ($Bn) AGR (%), 2009-2017
  • Table 4.9 Global Enbrel Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.10 Global Remicade Market Forecast: Revenues ($bn) AGR (%), 2009-2017
  • Table 4.11 Global Remicade Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.12 Global Taltz Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.13 Global Otezla Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.14 Global Cosentyx Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 4.15 Global Others Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.1 Global Skin Infection Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
  • Table 5.2 Skin Infection Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 5.3 Global Skin Infection Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 5.4 Global Cubicin Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.5 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 5.6 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.7 Global Canesten Market Forecast: Revenues ($bn) AGR (%), 2011-2017
  • Table 5.8 Global Canesten Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.9: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), 2010-2017
  • Table 5.10 Global Valtrex Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.11 Global Bactroban Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.12 Global Lamisil Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
  • Table 5.13 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.1 Global Acne Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
  • Table 6.2 Global Acne Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 6.3 Global Acne Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 6.4 Global Epiduo Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.5 Global Solodyn Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.6 Global Claravis Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.7 Global Aczone Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.8 Global Differin Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.9 Global Absorica/ Epirus Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.10 Global Ziana Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.11 Global Doryx Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2016-2028
  • Table 6.12 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 7.1 Global Dermatitis Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
  • Table 7.2 Global Dermatitis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 7.3 Global Dermatitis Drugs Market by Drugs Class: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 7.4 Global Bepanthen/ Bepanthol Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 7.5 Global Elocon Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 7.6 Global Protopic Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 7.7 Global Dermovate Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 7.8 Others Dermatitis Drugs Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2016-2028
  • Table 8.1 Global Dermatological Drugs Market by Region: Revenue ($bn), 2016 and 2017
  • Table 8.2 Global Dermatological Drugs Market Forecast, by Region: Revenues ($ bn), AGR (%), CAGR (%), 2016-2028
  • Table 8.3 Global Dermatological Drugs Market by Region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 8.4 Global Dermatological Drugs Market by Region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 9.2 North America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 9.3 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 9.4 Canada Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 10.1 Global Dermatological Drugs Market by Country/Sub-region: Revenue ($bn) and Market Share (%), 2017
  • Table 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 10.3 Europe Dermatological Drugs Market Forecast, By Country: Revenues ($ bn), AGR (%), CAGR (%), 2016-2028
  • Table 10.4 Europe Dermatological Drugs Market by Country/Sub-region: CAGR (%), 2018-2022, 2022-2028, 2018-2028
  • Table 10.5 Germany Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 10.6 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 10.7 U.K. Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 10.8 Italy Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 10.9 Spain Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 10.10 Rest of Europe Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 11.2 Asia-Pacific Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 11.3 China Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 11.4 Japan Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 11.5 India Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 11.6 Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2016-2028 ($ bn, AGR %, CAGR %)
  • Table 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 12.2 Latin America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 12.3 Brazil Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 12.4 Mexico Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 12.5 Rest of Latin America Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 13.2 Middle East & Africa (MEA) Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 13.3 Saudi Arabia Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2016-2028
  • Table 13.4 South Africa Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 13.5 Rest of MEA Dermatological Drugs Market Forecast, 2016-2028 ($bn, AGR %, CAGR %)
  • Table 14.1 Galderma: Overview, 2018
  • Table 14.2 Nestle: Revenue ($m), AGR (%), 2013-2017
  • Table 14.3. Johnson & Johnson: Overview, 2018
  • Table 14.4 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
  • Table 14.5 GlaxoSmithKline plc: Overview, 2018
  • Table 14.6 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2013-2017
  • Table 14.7 GlaxoSmithKline: Dermatological Drugs Pipeline, 2018
  • Table 14.8 Pfizer, Inc.: Overview, 2018
  • Table 14.9 Pfizer, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 14.10 LEO Pharma A/S: Overview, 2018
  • Table 14.11 LEO Pharma A/S: Revenue ($m), AGR (%), 2013-2017
  • Table 14.12 AbbVie Inc.: Overview, 2018
  • Table 14.13 AbbVie Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 14.14 Novartis: Overview, 2018
  • Table 14.15 Novartis: Revenue ($m), AGR (%), 2013-2017
  • Table 14.16 Amgen, Inc.: Overview, 2018
  • Table 14.17 Amgen, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 14.18 Merck & Co., Inc.: Overview, 2018
  • Table 14.19 Merck & Co., Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 14.20 Bayer AG: Overview, 2018
  • Table 14.21 Bayer AG: Revenue ($m), AGR (%), 2013-2017
  • Table 15.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2018
  • Table 15.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2018
  • Table 15.3 Psoriasis Drugs Pipeline: Phase 1 Drugs, 2018
  • Table 15.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2018
  • Table 15.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2018
  • Table 15.6 Acne Drugs Pipeline: Phase 3 Drugs, 2018
  • Table 15.7 Acne Drugs Pipeline: Phase 2 Drugs, 2018
  • Table 15.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2018
  • Table 15.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2018
  • Table 15.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
  • Table 15.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2018
  • Table 15.12 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2018
  • Table 16.1 SWOT Analysis of the Global Dermatological Drugs Market, 2018-2028
  • Table 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), and CAGR (%), 2017, 2022 and 2028
  • Table 17.2 Global Dermatological Drugs Market by Drugs Class: Revenue ($bn), and Market Share (%), 2017
  • Table 17.3 Global Dermatological Drugs Market by Region: Revenue ($bn), 2016, 2022, 2028
  • Table 17.4 Global Dermatological Drugs Market by Drug Class: CAGR (%), 2017, 2022, 2028

List of Figures

  • Figure 1.1 Global Dermatological Drugs Market Segmentation Overview
  • Figure 2.1 Anatomy of Human Skin
  • Figure 3.1 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2017
  • Figure 3.2 World Dermatological Drugs Market: Revenues ($bn), by Drugs Class, 2017
  • Figure 3.3 Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2016-2028
  • Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2018-2022
  • Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2022-2028
  • Figure 3.6 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2018-2028
  • Figure 3.7 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2017
  • Figure 3.8 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2022
  • Figure 3.9 Global Dermatological Drugs Market by Drugs Class: Market Share (%), 2028
  • Figure 4.1 World Psoriasis Drugs Market: Revenues ($bn), by Drugs Class, 2017
  • Figure 4.2 Global Psoriasis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.3 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2017
  • Figure 4.4 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2022
  • Figure 4.5 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2028
  • Figure 4.6 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 4.7 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.8 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 4.9 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.10 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2009-2017
  • Figure 4.11 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.12 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2009-2017
  • Figure 4.13 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.14 Global Taltz Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.15 Global Otezla Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.16 Global Cosentyx Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 4.17 Global Others Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.1 World Skin Infection Drugs Market: Revenues ($bn), by Drugs Class, 2017
  • Figure 5.2 Global Skin Infection Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.3 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2017
  • Figure 5.4 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2022
  • Figure 5.5 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2028
  • Figure 5.6 Global Cubicin Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.7 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 5.8 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.9 Global Canesten Market Forecast: Revenue ($bn) AGR (%), 2011-2017
  • Figure 5.10 Global Canesten Market Forecast: Revenue ($Bn) AGR (%), 2016-2028
  • Figure 5.11 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2010-2017
  • Figure 5.12 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.13 Global Bactroban Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.14 Global Lamisil Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 5.15 Global Others Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.1 World Acne Drugs Market: Revenues ($bn), by Drugs Class, 2017
  • Figure 6.2 Global Acne Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2017
  • Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2022
  • Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2028
  • Figure 6.6 Global Epiduo Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.7 Global Solodyn Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.8 Global Claravis Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.9 Global Aczone Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.10 Global Differin Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.11 Global Absorica/ Epirus Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.12 Global Ziana Market Forecast: Revenue ($bn) AGR (%), 2016-2023
  • Figure 6.13 Global Doryx Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 6.14 Global Others Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 7.1 World Dermatitis Drugs Market: Revenues ($bn), by Drugs Class, 2017
  • Figure 7.2 Global Dermatitis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2017
  • Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2022
  • Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2028
  • Figure 7.6 Global Bepanthen/ Bepanthol Market Forecast: Revenue ($bn), AGR (%), 2016-2028
  • Figure 7.7 Global Elocon Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 7.8 Global Protopic Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 7.9 Global Dermovate Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 7.10 Global Other Dermatitis Market Forecast: Revenue ($bn) AGR (%), 2016-2028
  • Figure 8.1 World Dermatological Drugs Market: Revenues ($bn) by Region, 2016
  • Figure 8.2 World Dermatological Drugs Market: Revenues ($bn) by Region, 2017
  • Figure 8.3 Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2016-2028
  • Figure 8.4 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2017
  • Figure 8.5 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2022
  • Figure 8.6 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2028
  • Figure 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 9.2 North America Dermatological Drugs Market: Market Shares (%) by Country, 2017
  • Figure 9.3 North America Dermatological Drugs Market: Market Shares (%) by Country, 2022
  • Figure 9.4 North America Dermatological Drugs Market: Market Shares (%) by Country, 2028
  • Figure 9.5 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 9.6 Canada Dermatological Drugs Market Forecast: Revenues ($ Bn), AGR (%), 2016-2028
  • Figure 10.1 Europe Dermatological Drugs Market: Revenues ($bn) by Country/Sub-region, 2017
  • Figure 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
  • Figure 10.3 Europe Dermatological Drugs Market: Market Shares (%) by Regional Market, 2017
  • Figure 10.4 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2022
  • Figure 10.5 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2028
  • Figure 10.6 Germany Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 10.7 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 10.8 U.K. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 10.9 Italy Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 10.10 Spain Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 10.11 Rest of Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 11.2 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2017
  • Figure 11.3 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2022
  • Figure 11.4 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2028
  • Figure 11.5 China Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
  • Figure 11.6 Japan Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
  • Figure 11.7 India Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 11.8 Rest of Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 12.2 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2017
  • Figure 12.3 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2022
  • Figure 12.4 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2028
  • Figure 12.5 Brazil Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
  • Figure 12.6 Mexico Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2016-2028
  • Figure 12.7 Rest of Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 13.2 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2017
  • Figure 13.3 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2022
  • Figure 13.4 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2028
  • Figure 13.5 Saudi Arabia Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 13.6 South Africa Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 13.7 Rest of MEA Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2016-2028
  • Figure 14.1 Nestle: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.2 Nestle: Business Segment Revenue Share (%), 2017
  • Figure 14.3 Nestle: Region Revenue Share (%), 2017
  • Figure 14.4 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.5 Johnson & Johnson: Business Segment Revenue Share (%), 2017
  • Figure 14.6 Johnson & Johnson: Region Revenue Share (%), 2017
  • Figure 14.7 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.8 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2017
  • Figure 14.9 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2017
  • Figure 14.10 GlaxoSmithKline plc: by Region Revenue Share (%), 2017
  • Figure 14.11 Pfizer, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.12 Pfizer, Inc.: Business Segment Revenue Share (%), 2017
  • Figure 14.13 Pfizer, Inc.: National Revenue Share (%), 2017
  • Figure 14.14 LEO Pharma A/S : Revenue ($m), AGR (%), 2013-2017
  • Figure 14.15 LEO Pharma A/S: Therapeutic Area Revenue Share (%), 2017
  • Figure 14.16 LEO Pharma A/S: Region Revenue Share (%), 2017
  • Figure 14.17 AbbVie Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.18 AbbVie Inc.: Bussiness Segment Revenue Share (%), 2017
  • Figure 14.19 Novartis: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.20 Novartis: Revenue, by Division, Share (%), 2017
  • Figure 14.21 Novartis: Revenue, by Region, Share (%), 2017
  • Figure 14.22 Amgen, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.23 Amgen, Inc.: Revenue, by Division, Share (%), 2017
  • Figure 14.24 Amgen, Inc.: Revenue, by Region, Share (%), 2017
  • Figure 14.25 Merck & Co., Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.26 Merck & Co., Inc.: Business Segment Revenue Share (%), 2017
  • Figure 14.27 Merck & Co., Inc.: Region Revenue Share (%), 2017
  • Figure 14.28 Bayer AG: Revenue ($m), AGR (%), 2013-2017
  • Figure 14.29 Bayer AG: Business Segment Revenue Share (%), 2017
  • Figure 14.30 Bayer AG: Region Revenue Share (%), 2017
  • Figure 16.1 Porter"s Five Force Analysis
  • Figure 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) 2017, 2022, 2028
  • Figure 17.2 World Dermatological Drugs Market: Revenues ($bn), by Drugs Class, 2017
  • Figure 17.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2017, 2022, 2028
  • Figure 17.4 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2017, 2022, 2028

COMPANIES LISTED

  • Abbott
  • AbbVie
  • Actavis
  • AET BioTech
  • Alkem Laboratories
  • Allergan
  • Almirall
  • Amgen
  • Anacor
  • Ascend Therapeutics
  • Astellas
  • Aurovindo
  • Barr Labs
  • Bayer
  • Betta Pharmaceuticals
  • Biocon/Mylan
  • Biofrontera
  • Biogen
  • Biovail Laboratories
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Brazilian Society of Dermatology
  • Cadila Healthcare
  • Calico
  • Can-Fite BioPharma
  • Cassiopea SpA
  • Celgene
  • Celltrion
  • Cempra
  • Cipher Pharmaceuticals
  • Cipla
  • Colorescience
  • Cubist Pharmaceuticals
  • Cutanea Life Sciences
  • Dow Pharmaceuticals Science
  • Dr Reddy's
  • Durata Therapeutics
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • FibroTx
  • Food and Drug Association (FDA)
  • Foamix
  • Fougera
  • Fujifilm
  • Galapagos NV
  • G&E Herbal Biotechnology
  • Galderma
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Heritage
  • Impax
  • Incyte
  • International Health Partners
  • Janssen Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • L'Oreal
  • LEO Pharma
  • Lupin
  • Maruho
  • Mayne Pharma
  • Medicis
  • Medison Pharma
  • Melinta Pharmaceuticals
  • Merck
  • Merz Pharmaceuticals
  • Mitsubishi Tanabe
  • MorphoSys
  • Mylan
  • NanoBio Corporation
  • National Psoriasis Foundation (NPF)
  • NeoStrata Compnay Inc
  • Nestle Skin Health
  • Novan
  • Novartis
  • Perriogo
  • Pfizer
  • PharmaPraxis
  • Photocure
  • Pierre Fabre
  • Provectus Biopharmaceuticals
  • QLT Inc
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Schering-Plough
  • Shanghai CP Buojian Pharmaceutical
  • Sidmak Labs
  • Sol-Gel Technologies Ltd
  • Sun Pharma
  • Sunovion
  • Takeda
  • Tanabe
  • Tanja Todberg
  • Taro Pharmaceuticals
  • Teva
  • Thesan Pharmaceuticals Inc
  • Topica Pharmaceuticals
  • UCB
  • Valeant
  • Vical
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Xenon Pharmaceuticals
  • Ziarco Group Limited
  • Zydus

List of Tables

  • Table 1.1 Dermatological Drugs Market Forecast by National Markets: Revenue ($bn), AGR (%) and CAGR (%), 2017-2027
  • Table 2.1 Clinical Trial Phases, 2016
  • Table 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn) and Market Shares (%), 2016
  • Table 3.2 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021, 2021-2027, 2016-2021
  • Table 3.4 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016, 2021 and 2027
  • Table 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn) and Market Shares (%), 2016
  • Table 4.2 Psoriasis Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 4.4 Humira Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 4.5 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 4.7 Stelara Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8 Enbrel Historical Sales by Company: Revenue ($bn) and AGR (%), 2008-2016
  • Table 4.9 Enbrel Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10 Remicade Historical Sales: Revenue ($bn), 2010-2016
  • Table 4.11 Remicade Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12 Taltz: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.13 Otezla Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.14 Cosentyx Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.15 Other Psoriasis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 5.2 Skin Infection Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 5.4 Cubicin Sales Forecast: Revenue($bn), AGR (%) and CAGR(%), 2016-2027
  • Table 5.5 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Table 5.6 Zyvox: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.7 Canesten: Historical Sales: Revenue ($bn), and AGR (%), 2011-2015
  • Table 5.8 Canesten: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.9 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 5.10 Valtrex: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.11 Bactroban: Historical Sales: Revenue ($bn) and AGR (%), 2010-2013
  • Table 5.12 Bactroban Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.13 Lamisil Novartis Sales Forecast: Revenue ($bn), AGR (%), and CAGR (%), 2016-2027
  • Table 5.14 Other Skin Infection Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 6.2 Acne Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 6.4 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.5 Solodyn (Valeant) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.6 Claravis (Teva) Sales Forecast: Revenue ($bn), AGR%, and CAGR (%), 2016-2027
  • Table 6.7 Aczone (Allergan) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR%), 2016-2027
  • Table 6.9 Absorica/Epuris Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%),
  • 2016-2027
  • Table 6.10 Ziana Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.11 Doryx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.12 Other Acne Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 7.2 Dermatitis Drugs Market: Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
  • Table 7.4 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.5 Elocon Sales Forecast: Revenue ($bn), AGR (%) CAGR (%), 2016-2027
  • Table 7.6 Protopic Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.7 Dermovate Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.8 Other Dermatitis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn) and Market Share (%), 2016
  • Table 8.2 Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2016-2027
  • Table 8.3 The Global Dermatological Drugs Market Forecast by Region: CAGR (%), 2016-2021, 2021-2027, and 2016-2027
  • Table 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016, 2021 and 2027
  • Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.6 US Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.7 The EU5 Dermatological Drugs Market by Country Revenue ($bn) and Market Share (%), 2016
  • Table 8.8 The EU5 Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016, 2021 and 2027
  • Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.13 The French Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%)and CAGR (%), 2016-2027
  • Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.15 The UK Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.17 The Italian Dermatological Drugs Market Forecast: ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.19 The Spanish Dermatological Drugs Market Forecast: Revenue($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.21 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.23 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%) and CAGR (%), 2016-2027
  • Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.25 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.27 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.29 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.30 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2016-2027
  • Table 8.31 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 9.1 Galderma: Company Overview, 2016
  • Table 9.2 Johnson & Johnson: Company Overview, 2016
  • Table 9.3 AbbVie: Company Overview, 2017
  • Table 9.4 GlaxoSmithKline: Company Overview, 2016
  • Table 9.5 GlaxoSmithKline: Dermatological Drugs Pipeline, 2016
  • Table 9.6 Pfizer: Company Overview, 2016
  • Table 9.7 LEO Pharma: Company Overview, 2016
  • Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2016
  • Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
  • Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
  • Table 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2016, 2021 and 2027
  • Table 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn) and Market Shares (%), 2016
  • Table 12.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2016, 2021 and 2027
  • Table 12.4 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027

List of Figures

  • Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2017
  • Figure 2.1 Anatomy of Human Skin
  • Figure 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn), 2016
  • Figure 3.2 The Global Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%) 2016-2027
  • Figure 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021
  • Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2021-2027
  • Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2027
  • Figure 3.6 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016
  • Figure 3.7 The Global Dermatological Drugs Market by Sector: Market Share (%), 2021
  • Figure 3.8 The Global Dermatological Drugs Market by Sector: Market Share (%), 2027
  • Figure 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn), 2016
  • Figure 4.2 Psoriasis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 4.4 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%) by Leading Drugs, 2021
  • Figure 4.5 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 4.6 Humira Historical Sales: Revenue ($bn) AGR (%), 2010-201
  • Figure 4.7 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.8 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Figure 4.9 Stelara Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.10 Enbrel Historical Sales by Company: Revenue ($bn), 2008-2015
  • Figure 4.11 Enbrel Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.12 Remicade Historical Sales: Revenue ($bn) and AGR (%), 2008-2016
  • Figure 4.13 Remicade Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.14 Taltz Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.15 Otezla Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.16 Cosentyx Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.17 Other Psoriasis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn), 2016
  • Figure 5.2 Skin Infection Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 5.4 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 5.5 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 5.6 Cubicin Sales Forecast: Revenue ($bn) AGR (%), 2016-2027
  • Figure 5.7 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 5.8 Zyvox: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.9 Canesten: Historical Sales: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 5.10 Canesten: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.11 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 5.12 Valtrex Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.13 Bactroban: Historical Sales: Revenue ($bn) AGR (%), 2010-2013
  • Figure 5.14 Bactroban Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.15 Lamisil Novartis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.16 Other Skin Infection Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn), 2016
  • Figure 6.2 Acne Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 6.6 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.7 Solodyn (Valeant) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.8 Claravis (Teva) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.9 Aczone (Allergan) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.10 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.11 Absorica/Epuris Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.12 Ziana Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.13 Doryx Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.14 Other Acne Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn), 2016
  • Figure 7.2 Dermatitis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 7.6 Bepanthen/ Bepanthol Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.7 Elocon Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.8 Protopic Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.9 Dermovate Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.10 Other Dermatitis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn), 2016
  • Figure 8.2 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016
  • Figure 8.3 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2021
  • Figure 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2027
  • Figure 8.5 US Dermatological Drugs Market Forecast: Revenue ($bn) AGR (%), 2016-2027
  • Figure 8.6 The EU5 Dermatological Drugs Market by Country: Revenue ($bn), 2016
  • Figure 8.7 Germany, France, UK, Italy, and Spain Dermatological Drugs Market Forecast: Revenue ($bn), 2016-2027
  • Figure 8.8 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016
  • Figure 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2021
  • Figure 8.10 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2027
  • Figure 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.13 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.14 The Italian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.15 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.16 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.17 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.18 The Indian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.19 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.20 The Russian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.21 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 11.1 Porter's Five Force Analysis of the Dermatological Drugs Market, 2016
  • Figure 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), 2016, 2021, 2027
  • Figure 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn), 2016
  • Figure 12.3 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027

Companies Listed

  • Abbott
  • AbbVie
  • Actavis
  • AET BioTech
  • Alkem Laboratories
  • Allergan
  • Almirall
  • Amgen
  • Anacor
  • Ascend Therapeutics
  • Astellas
  • Aurovindo
  • Barr Labs
  • Bayer
  • Betta Pharmaceuticals
  • Biocon/Mylan
  • Biofrontera
  • Biogen
  • Biovail Laboratories
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Brazilian Society of Dermatology
  • Cadila Healthcare
  • Can-Fite BioPharma
  • Cassiopea SpA
  • Celgene
  • Celltrion
  • Cempra
  • Cipher Pharmaceuticals
  • Cipla
  • Cubist Pharmaceuticals
  • Cutanea Life Sciences
  • Dow Pharmaceuticals Science
  • Dr Reddy's
  • Durata Therapeutics
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • Food and Drug Association (FDA)
  • Foamix
  • Fougera
  • Fujifilm
  • G&E Herbal Biotechnology
  • Galderma
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Heritage
  • Impax
  • Incyte
  • Janssen Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • L'Oreal
  • LEO Pharma
  • Lupin
  • Maruho
  • Mayne Pharma
  • Medicis
  • Medison Pharma
  • Melinta Pharmaceuticals
  • Merck
  • Merz Pharmaceuticals
  • Mitsubishi Tanabe
  • MorphoSys
  • Mylan
  • NanoBio Corporation
  • National Psoriasis Foundation (NPF)
  • NeoStrata Compnay Inc
  • Nestle Skin Health
  • Novan
  • Novartis
  • Perriogo
  • Pfizer
  • PharmaPraxis
  • Photocure
  • Pierre Fabre
  • Provectus Biopharmaceuticals
  • QLT Inc
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Schering-Plough
  • Shanghai CP Buojian Pharmaceutical
  • Sidmak Labs
  • Sol-Gel Technologies Ltd
  • Sun Pharma
  • Sunovion
  • Takeda
  • Tanabe
  • Tanja Todberg
  • Taro Pharmaceuticals
  • Teva
  • Thesan Pharmaceuticals Inc
  • Topica Pharmaceuticals
  • UCB
  • Valeant
  • Vical
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Xenon Pharmaceuticals
  • Zydus
Back to Top